Norris Medicines Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 210607,
    "name": "Norris Medicines",
    "stock_name": "Norris Medicines",
    "full_name": "Norris Medicines Ltd",
    "name_url": "stocks-analysis/norris-medicines",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "16.75",
    "chg": -0.15,
    "chgp": "-0.89%",
    "dir": -1,
    "prev_price": "16.90",
    "mcapval": "16.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524414,
    "symbol": "",
    "ind_name": "Trading & Distributors",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE744C01029",
    "curr_date": "Dec 26",
    "curr_time": "",
    "bse_nse_vol": "212 ",
    "exc_status": "Active",
    "traded_date": "Dec 26, 2025",
    "traded_date_str": "2025 12 26",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/norris-medicines-210607-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Norris Medicines Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/norris-medicines-ltd-is-rated-strong-sell-3771207",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/NorrisMedicines_mojoScore_3771207.png",
        "date": "2025-12-26 15:12:32",
        "description": "Norris Medicines Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 30 June 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 December 2025, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance."
      },
      {
        "title": "Norris Medicines Sees Revision in Market Evaluation Amid Challenging Financial Trends",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/norris-medicines-downgraded-to-strong-sell-amid-weak-fundamentals-and-bearish-outlook-3753298",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/NorrisMedicines_mojoScore_3753298.png",
        "date": "2025-12-09 10:10:19",
        "description": "Norris Medicines has experienced a revision in its market evaluation, reflecting shifts in key analytical parameters that highlight ongoing challenges in its financial and operational performance. The changes in assessment metrics underscore the company’s current position within the Trading & Distributors sector and its microcap status."
      },
      {
        "title": "Norris Medicines Stock Falls to 52-Week Low of Rs.14 Amidst Prolonged Downtrend",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/norris-medicines-stock-hits-52-week-low-amidst-continued-downtrend-3746772",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/NorrisMedicines_priceRelatedfactors_3746772.png",
        "date": "2025-12-04 12:42:02",
        "description": "Norris Medicines has reached a new 52-week low of Rs.14, marking a significant decline amid a sustained downward trend. The stock has underperformed its sector and broader market indices, reflecting ongoing pressures on the company’s financial and market position."
      },
      {
        "title": "Norris Medicines Stock Falls to 52-Week Low of Rs.14.02 Amidst Market Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/norris-medicines-stock-falls-to-52-week-low-of-rs1402-amidst-weak-fundamentals-3743429",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/NorrisMedicines_priceRelatedfactors_3743429.png",
        "date": "2025-12-03 09:53:21",
        "description": "Norris Medicines has reached a new 52-week low of Rs.14.02, marking a significant decline in its stock price amid broader market fluctuations and sector underperformance. The stock's recent movement reflects ongoing challenges within the company’s financial metrics and market positioning."
      },
      {
        "title": "Norris Medicines Stock Hits 52-Week Low at Rs.14.02 Amid Market Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/norris-medicines-stock-hits-52-week-low-amidst-weak-financial-metrics-3743427",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/NorrisMedicines_priceRelatedfactors_3743427.png",
        "date": "2025-12-03 09:53:09",
        "description": "Norris Medicines has reached a new 52-week low of Rs.14.02, marking a significant decline in its stock price amid broader market fluctuations and sector underperformance. The stock's current trading levels reflect ongoing pressures within the Trading & Distributors sector, contrasting with the broader market's relative strength."
      },
      {
        "title": "Norris Medicines Stock Falls to 52-Week Low of Rs.14.5 Amidst Underperformance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/norris-medicines-stock-falls-to-52-week-low-of-rs145-amidst-weak-financial-metrics-3738366",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/NorrisMedicines_priceRelatedfactors_3738366.png",
        "date": "2025-12-01 11:12:06",
        "description": "Norris Medicines has reached a new 52-week low of Rs.14.5 today, marking a significant decline in its stock price amid continued underperformance relative to its sector and broader market indices."
      },
      {
        "title": "Norris Medicines Stock Falls to 52-Week Low of Rs.14.5 Amidst Market Underperformance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/norris-medicines-stock-falls-to-52-week-low-of-rs145-amidst-weak-financial-metrics-3738361",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/NorrisMedicines_priceRelatedfactors_3738361.png",
        "date": "2025-12-01 11:11:57",
        "description": "Norris Medicines has reached a new 52-week low of Rs.14.5, marking a significant decline in its stock price as it continues to underperform relative to its sector and broader market indices. The stock's recent movement reflects ongoing challenges within the company’s financial metrics and market positioning."
      },
      {
        "title": "Norris Medicines Q2 FY26: Deepening Losses Despite Revenue Growth Signal Structural Distress",
        "link": "https://www.marketsmojo.com/news/result-analysis/norris-medicines-q2-fy26-deepening-losses-despite-revenue-growth-signal-structural-distress-3718705",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/NorrisMedicines_quaterlyResult_3718705.png",
        "date": "2025-11-18 15:49:54",
        "description": "Norris Medicines Limited, the Ankleshwar-based pharmaceutical manufacturer and distributor, reported a troubling second quarter for FY2026, with net losses widening to ₹0.72 crores despite a 57.48% year-on-year revenue increase. The micro-cap company, valued at just ₹15.00 crores, continues to struggle with operational inefficiencies and negative profitability metrics that have plagued its performance for multiple quarters. Trading at ₹15.93 on November 18, 2025, the stock reflects investor scepticism about the company's ability to achieve sustainable profitability."
      },
      {
        "title": "How has been the historical performance of Norris Medicines?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-norris-medicines-3704012",
        "imagepath": "",
        "date": "2025-11-15 00:22:00",
        "description": "Answer:\nThe historical performance of Norris Medicines shows a declining trend in net sales and profitability over the years, with significant losses reported in recent periods.\n\nBreakdown:\nNorris Medicines has experienced a downward trajectory in net sales, decreasing from 12.25 Cr in Mar'21 to 5.82 Cr in Mar'25. The total operating income followed a similar pattern, dropping from 16.27 Cr in Mar'19 to 5.82 Cr in Mar'25. The company's total expenditure, excluding depreciation, also decreased from 13.99 Cr in Mar'21 to 6.08 Cr in Mar'25, yet the operating profit (PBDIT) remained negative, with a loss of -0.20 Cr in Mar'25 compared to a profit of 0.93 Cr in Mar'23. Profit before tax has consistently been negative, culminating in a loss of -1.18 Cr in Mar'25. The profit after tax also reflected losses, amounting to -1.24 Cr in Mar'25, indicating persistent financial challenges. The company's total liabilities..."
      }
    ],
    "total": 246,
    "sid": "210607",
    "stock_news_url": "https://www.marketsmojo.com/news/norris-medicines-210607"
  },
  "announcements": [
    {
      "caption": "Intimation Regarding Completion Of NAFDAC Audit (Nigeria) Of Norris Medicines Limited.",
      "datetime": "12-Dec-2025",
      "details": "As per attachment.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Resignation of Director",
      "datetime": "12-Dec-2025",
      "details": "As per attachment",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order",
      "datetime": "11-Dec-2025",
      "details": "Intimation regarding Order passed by Honble High Court in Criminal Appeal No. 89 of 2020.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Norris Medicines Ltd is Rated Strong Sell

2025-12-26 15:12:32

Norris Medicines Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 30 June 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 December 2025, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Norris Medicines Sees Revision in Market Evaluation Amid Challenging Financial Trends

2025-12-09 10:10:19

Norris Medicines has experienced a revision in its market evaluation, reflecting shifts in key analytical parameters that highlight ongoing challenges in its financial and operational performance. The changes in assessment metrics underscore the company’s current position within the Trading & Distributors sector and its microcap status.

Norris Medicines Stock Falls to 52-Week Low of Rs.14 Amidst Prolonged Downtrend

2025-12-04 12:42:02

Norris Medicines has reached a new 52-week low of Rs.14, marking a significant decline amid a sustained downward trend. The stock has underperformed its sector and broader market indices, reflecting ongoing pressures on the company’s financial and market position.

Norris Medicines Stock Falls to 52-Week Low of Rs.14.02 Amidst Market Pressure

2025-12-03 09:53:21

Norris Medicines has reached a new 52-week low of Rs.14.02, marking a significant decline in its stock price amid broader market fluctuations and sector underperformance. The stock's recent movement reflects ongoing challenges within the company’s financial metrics and market positioning.

Norris Medicines Stock Hits 52-Week Low at Rs.14.02 Amid Market Pressure

2025-12-03 09:53:09

Norris Medicines has reached a new 52-week low of Rs.14.02, marking a significant decline in its stock price amid broader market fluctuations and sector underperformance. The stock's current trading levels reflect ongoing pressures within the Trading & Distributors sector, contrasting with the broader market's relative strength.

Norris Medicines Stock Falls to 52-Week Low of Rs.14.5 Amidst Underperformance

2025-12-01 11:12:06

Norris Medicines has reached a new 52-week low of Rs.14.5 today, marking a significant decline in its stock price amid continued underperformance relative to its sector and broader market indices.

Norris Medicines Stock Falls to 52-Week Low of Rs.14.5 Amidst Market Underperformance

2025-12-01 11:11:57

Norris Medicines has reached a new 52-week low of Rs.14.5, marking a significant decline in its stock price as it continues to underperform relative to its sector and broader market indices. The stock's recent movement reflects ongoing challenges within the company’s financial metrics and market positioning.

Norris Medicines Q2 FY26: Deepening Losses Despite Revenue Growth Signal Structural Distress

2025-11-18 15:49:54

Norris Medicines Limited, the Ankleshwar-based pharmaceutical manufacturer and distributor, reported a troubling second quarter for FY2026, with net losses widening to ₹0.72 crores despite a 57.48% year-on-year revenue increase. The micro-cap company, valued at just ₹15.00 crores, continues to struggle with operational inefficiencies and negative profitability metrics that have plagued its performance for multiple quarters. Trading at ₹15.93 on November 18, 2025, the stock reflects investor scepticism about the company's ability to achieve sustainable profitability.

How has been the historical performance of Norris Medicines?

2025-11-15 00:22:00

Answer: The historical performance of Norris Medicines shows a declining trend in net sales and profitability over the years, with significant losses reported in recent periods. Breakdown: Norris Medicines has experienced a downward trajectory in net sales, decreasing from 12.25 Cr in Mar'21 to 5.82 Cr in Mar'25. The total operating income followed a similar pattern, dropping from 16.27 Cr in Mar'19 to 5.82 Cr in Mar'25. The company's total expenditure, excluding depreciation, also decreased from 13.99 Cr in Mar'21 to 6.08 Cr in Mar'25, yet the operating profit (PBDIT) remained negative, with a loss of -0.20 Cr in Mar'25 compared to a profit of 0.93 Cr in Mar'23. Profit before tax has consistently been negative, culminating in a loss of -1.18 Cr in Mar'25. The profit after tax also reflected losses, amounting to -1.24 Cr in Mar'25, indicating persistent financial challenges. The company's total liabilities...

View All News